Immune Profiles of Patients with Chronic Idiopathic UrticariaPiconi S.a · Trabattoni D.b · Iemoli E.a · Fusi M.L.b · Villa M.L.b · Milazzo F.a · Clerici M.b
aFirst Department of Infectious Disease and Allergy Unit, L. Sacco Hospital, bChair of Immunology, University of Milan, DISP LITA Vialba, Milan, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: The immunologic characterization of chronic idiopathic urticaria (CIU) is still incomplete. In particular, it is not known if positivity to the intradermal autologous serum skin test (ASST) identifies an immunologic subset of CIU patients. Methods: Nineteen CIU patients and 15 healthy controls were enrolled in the study. A diagnostic flowchart was designed to select CIU patients, who were then analyzed by ASST. Cytokine and chemokine production and the expression of adhesion molecules was measured in patients and controls. Results: In CIU patients compared to controls, it was found that (1) TNF-α, IL-10, MIP-1α and RANTES production was augmented and IL-2 and INF-γ reduced, and (2) CD44, CD11a and CD62L expression on CD4 and CD8 cells was augmented. Additionally, TNF-α and chemokine production was significantly increased in CIU patients with a negative ASST (p–; n = 10) compared to patients with a positive response to the test. Conclusions: The presence of an inflammatory process in CIU patients is suggested by the findings that the production of both TNF-α and chemokines as well as the expression of adhesion molecules is increased in these patients. Similarly to what is seen in rheumatoid arthritis, augmented IL-10 production might be secondary to the attempt to hamper the inflammatory milieu. Immune profiles are particularly altered in CIU p– patients, in whom a more aggressive therapeutic strategy might be considered.
© 2002 S. Karger AG, Basel
- Cooper KD: Urticaria and angioedema: Diagnosis and evaluation. J Am Acad Dermatol 1991;25:166–175.
- Greaves MW: Chronic urticaria. N Engl J Med 1995;332:1767–1772.
- Tong LJ, Balakrishnan G, Kochan JP, Kinet JP, Kaplan AP: Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997;99:461–465.
- Gruber BL, Baeza M, Marchese MJ, Agnello V, Kaplan AP: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213–217.
- Hide M, Francis DM, Grattan CE, Hakimi J, Kocham JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause for histamine release in chronic urticaria. N Engl J Med 1993;328:1599–1604.
- Niimi N, Francis DM, Kermani F, O’Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996;106:1001–1006.
- Ferrer M, Kinet JP, Kaplan AP: Comparative studies of functional and binding assays for IgG anti-Fc (epsilon) RI alpha (alpha sub-unit) in chronic urticaria. J Allergy Clin Immunol 1998;101:672–676.
- Kikuchi Y, Kaplan AP: Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001;107:1056–1062.
- MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM: Molecular identification of an IgE-dependent histamine-releasing factor. Science 1995;269:688–690.
- Leznoff A, Sussman GL: Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: A study of 90 patients. J Allergy Clin Immunol 1989;84:66–71.
- Fiebiger E, Maurer D, Holub M, Reininger B, Hartmann G, Woisetschlager M, Kinet JP, Stingl G: Serum IgG autoantibodies directed against the alpha chain of FcεRI: A selective marker and pathogenic factor for a distinct subset of chronic urticaria patients. J Clin Invest 1995;96:2606–2612.
- Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW: Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999;40:443–450.
Kermani F, Niimi N, Francis DM, O’Donnell B, Black AK, Hafizi S, Yacoub M, Greaves MV, Barr RM: Characterization of a novel mast cell-specific histamine releasing activity in chronic idiopathic urticaria. J Invest Dermatol 1995;105:452.
- Mekori YA, Giorno RC, Anderson P, Kohler PF: Lymphocyte subpopulations in the skin of patients with chronic urticaria. J Allergy Clin Immunol 1983;72:681–684.
- Elias J, Boss E, Kaplan AP: Studies of the cellular infiltrate of chronic idiopathic urticaria: Prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986;78:914–918.
- Barlow R, Ross EL, MacDonald D, Black AK, Greaves MW: Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol 1994;131:641–647.
- Tillie-Leblond I, Gosset P, Janin A, Dalenne R, Joseph M, Wallaert B, Tonnel AB: Tumor necrosis factor-alpha release during systemic reaction in cold urticaria. J Allergy Clin Immunol 1994;93:501–509.
- Hermes B, Prochazka AK, Haas N, Jurgovsky K, Sticherling M, Henz BM: Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999;103:307–314.
- Grattan CEH, Wallington TB, Warin RP, Kennedy CT, Bradfield JW: A serological mediator in chronic idiopathic urticaria – a clinical, immunological and histological evaluation. Br J Dermatol 1986;114:583–590.
- Frew AJ, Kay AB: Eosinophils and T-lymphocytes in late-phase allergic reactions. J Allergy Clin Immunol 1990;85:533–539.
- Wershil BK, Wang ZS, Gordon JR, Galli SJ: Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-α. J Clin Invest 1991;87:446–455.
- Okayama Y, Bradding P, Tunon-de-Lara JM, Holgate ST, Church MK: Cytokine production by human mast cells. Chem Immunol 1995;61:114–134.
- Hamawy MM, Mergenhagen SE, Siraganian RP: Adhesion molecules as regulators of mast-cell and basophil function. Immunol Today 1994;15:62–66.
- Hemler ME: VLA proteins in the integrin family: Structures, functions and their role on leukocytes. Annu Rev Immunol 1990;8:365–369.
- Springer TA: Adhesion receptors of the immune system. Nature 1990;346:425–429.
Patarroyo ME, Makgaba MW: Leukocyte adhesion to cells in immune and inflammatory responses. Lancet 1989;ii:1139–1145.
- Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301–305.
- Parish NM, Brennan FR, Cooke A: Anti-CD44 treatment does not prevent the extravasation of autopathogenic T cells to the thyroid in experimental autoimmune thyroiditis. Immunology 1999;97:533–539.
- Haas N, Iwen W, Grabbe J, Hamann K, Czarnetzki BM: Beta 2-integrins in different forms of urticaria. Br J Dermatol 1995;133:48–53.
- De Vries IJ, Langeveld-Wildschut EG, Van Reijsen FC, Dubois GR, Van den Hoek JA, Bihari IC, van Wichen D, de Weger RA, Knol EF, Thepen T, Bruijnzeel-Koomen CA: Adhesion molecule expression on skin endothelia in atopic dermatitis: Effects of TNF-α and IL-4. J Allergy Clin Immunol 1998;102:461–468.
- Haas N, Iwen W, Grabbe J, Uchanska-Ziegler B, Czarnetzki BM: MHC class II antigen expression is increased in different forms of urticaria. Int Arch Allergy Immunol 1996;109:177–182.
- Czarnetzki BM, Zwadlo-Klarwasser GZ, Brocker EB, Sorg C: Macrophage subsets in different types of urticaria. Arch Dermatol Res 1990;282:93–97.
- Kuna P, Reddigari S, Schall TJ, Rucinsky D, Viksman MY, Kaplan AP: RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992;149:636–642.
- Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 1993;11:165–190.
- Lubberts E, Joosten LAB, Helsen MMA, Van den Berg WB: Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998;10:361–369.
- Harvey RP, Wegs J, Schocket AL: A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981;68:262–266.
Barlow RJ, Black AK, Greaves MW: Treatment of severe chronic urticaria with cyclosporin A. Eur J Dermatol 1993;3:272–275.
- Paradis L, Lavoie A, Brunet C, Bedard PM, Herbert J: Effects of systemic corticosteroids on cutaneous histamine secretion and histamine-releasing factor in patients with chronic idiophatic urticaria. Clin Exp Allergy 1996;26:815–820.
- Greaves MW: Chronic urticaria. J Allergy Clin Immunol 2000;105:664–672.
Iemoli E, Piconi S, Landonio S, Quirino T: Chronic urticaria etiologic and therapeutic aspects in 90 patients. Allergy 2000;S63:10–12.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.